Infusense
Private Company
Funding information not available
Overview
Infusense is developing a portable electrochemical biosensor platform designed for the rapid and precise quantification of specific drugs, including anesthetics like propofol and illicit substances like fentanyl. The technology, supported by peer-reviewed research and significant non-dilutive grant funding, demonstrates nanomolar detection limits and analysis times of just minutes. The company is in a pre-revenue, R&D-focused stage, targeting applications in controlled anesthesia delivery and substance toxicity testing, with a clear path toward regulatory submission and commercialization.
Technology Platform
Electrochemical biosensor platform utilizing polymeric membrane-modified voltammetric sensors for the rapid, precise, and portable quantification of lipophilic drug analytes in biological samples.
Opportunities
Risk Factors
Competitive Landscape
Infusense competes in the broad point-of-care diagnostics and biosensor market. Direct competitors include companies developing alternative rapid drug tests (e.g., lateral flow assays for fentanyl) and other electrochemical sensing startups. Its key differentiator is the platform's proven, peer-reviewed sensitivity for specific hydrophobic drugs at nanomolar levels.